1stOncology™: Cancer Intelligence Service – Page 3805 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

myNEO evolves into myNEO Therapeutics to reflect its new strategy to develop off-the-shelf cancer vaccine immunotherapeutics

On October 25, 2023 myNEO, a biotech company focused on exploiting "dark genome" targets to develop novel therapeutic cancer vaccines, reported its new name – myNEO Therapeutics (Press release, myNEO Therapeutics , OCT 25, 2023, View Source [SID1234640211]). The new name reflects the company’s transition from an immunogenomic profiling expert towards an integrated drug discovery company focused on the development of a pipeline of therapeutic cancer vaccines.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Since the company was founded in 2018, it has developed and patented proprietary Artificial Intelligence (AI) algorithms that are state-of-the art in identifying novel cancer antigens, allowing optimal selection of the best cancer targets for use in immunotherapies.

Building on this deep knowledge, internal research efforts have revealed a novel class of lncRNA-derived "dark genome" antigens which myNEO Therapeutics has named "camyotopes". These tumor-derived epitopes originate from the non-coding part of the genome, or dark genome, which is increasingly associated with a variety of diseases including cancer. Preclinical validation of these targets has reinforced the company’s belief that camyotopes are a potentially game changing class of tumor antigens for cancer immunotherapy for the many patients currently lacking sufficient actionable immunogenic targets.

Following the discovery and validation of a number of camyotopes, myNEO Therapeutics has made rapid progress in advancing its first therapeutic product, CAMYO-01, towards the clinic. CAMYO-01 incorporates a pool of colorectal cancer-specific camyotopes formulated into an mRNA-based vaccine.

Unlike personalized vaccines that require patient-unique targets and upfront genomic analysis of each patient’s tumor, camyotopes are conserved in more than 95% of the target cancer patient population. As such, treatments based on these targets can be made readily available off-the-shelf with no need for expensive and time-consuming tumor screening thereby improving access and providing a significant benefit to patients.

In addition, myNEO Therapeutics has shown that selected camyotopes are specifically translated as well as highly abundant in cancer cells which is expected to limit off-target toxicity and de-risk immune escape which can render treatment ineffective.

myNEO Therapeutics is currently performing additional pre-clinical validation experiments to prepare for the first phase of clinical development for CAMYO-01, which is expected to start before the end of 2024.

Cedric Bogaert, co-founder and CEO of myNEO Therapeutics commented: " This evolution of our corporate identity to myNEO Therapeutics marks a pivotal milestone in our strategic development and illustrates the significant progress we are making in realizing our vision. CAMYO-01 is only the start of our plan to develop a robust pipeline of therapeutic cancer vaccines based on our unique technology platform and insights into the dark genome which we believe can unlock the future of cancer immunotherapy for the benefit of a broad population of patients. "

AGC Biologics Signs TCR-T Cell Services Agreement to Support Medigene’s New Cell Therapy Product

On October 25, 2023 AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), reported a new service agreement with Medigene AG (Medigene, the "Company", FSE: MDG1, Prime Standard) (Press release, MediGene, OCT 25, 2023, View Source [SID1234636354]). Under the agreement, AGC Biologics is providing autologous production for a next-generation-therapy product focused on the treatment of solid cancers, supporting Medigene’s IND filing and clinical trials.

With the product currently in the pre-clinical phase, AGC Biologics will perform a process transfer and clinical manufacturing of Medigene’s product candidate at the CDMO’s Cell and Gene Center of Excellence in Milan.

"The growth of T cell immunotherapies in recent years has been astonishing. Although complex to manufacture, they offer unique therapeutic effects for patients in need," said Luca Alberici, General Manager of AGC Biologics Milan. "Intricate cell therapy projects are not unique to our team, and we are eager to take on this challenge and help produce this cell therapy product with Medigene, a company truly focused on innovation in the field of solid tumor treatments."

According to recent industry research from Roots Analysis, T cell immunotherapies are poised for greater than 30 percent growth rate over the next decade, thanks to their unique ability to target cancer cells and promising early clinical data. Being a living therapy, T cell therapies are complex drug products to manufacture at GMP scales. AGC Biologics’ Milan location has 30 years of experience in the cell and gene field and expertise with complex advanced cell therapy projects, such as these. The core team has guided three cell therapy products from development to commercial stages and has manufactured hundreds of batches of cell therapies for clinical and commercial usage.

"This is a critical first step in ensuring that our lead product candidate MDG1015, a third generation TCR-T therapy combining our optimal affinity TCR targeting NY-ESO-1/LAGE-1a with our PD1-41BB costimulatory switch protein, is ready for GMP clinical evaluation," said Selwyn Ho, CEO at Medigene. "We are delighted to partner with AGC Biologics as we advance towards MDG1015’s phase I clinical milestone and look forward to its further development and delivering a potentially best-in-class, differentiated TCR-T therapy for patients with solid tumors."

To learn more about AGC Biologics’ global cell therapy services visit www.agcbio.com/capabilities/cell-therapy, go to www.agcbio.com/capabilities/viral-vector and learn more about the CDMO’s viral vector offerings.

Fulgent Announces Two Poster Presentations at SITC 2023 Annual Meeting

On October 25, 2023 Fulgent Genetics, Inc. (NASDAQ: FLGT) ("Fulgent" or the "Company"), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, reported two upcoming poster presentations at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 38th Annual Meeting, to be held virtually and at the San Diego Convention Center from November 1 to 5, 2023 (Press release, Fulgent Genetics, OCT 25, 2023, View Source [SID1234636353]).

Details on Fulgent’s poster presentations at SITC (Free SITC Whitepaper) are as follows:

Title: Critical clinical evaluation of plasma to tumor tissue concordance by cancer type using Illumina’s cell-free ctTSO500 commercial liquid biopsy assay
Date and Time: Saturday, November 4 from 9:00 a.m. to 8:30 p.m. PDT
Abstract/Poster #: 222-B

Title: FID-007: Nanoencapsulated Paclitaxel Derived from a Novel Nano-Drug Delivery Platform
Date and Time: Saturday, November 4 from 9:00 a.m. to 8:30 p.m. PDT
Abstract/Poster #: 782-B

The posters will be available following the presentations on the Investor Relations section of the company’s website at View Source

About FID-007

FID-007 consists of paclitaxel encapsulated in a polyethyloxazoline (PEOX) polymer excipient designed to enhance PK, biodistribution, and tolerability. In addition to allowing the drug to remain in solution until it can enter a cancer cell, the PEOX nanoparticle is designed to preferentially deliver paclitaxel to the tumor through the leaky hyperpermeable vasculature.

Flashpoint Therapeutics Announces $10M Seed Financing Led by Beta Lab to Pioneer Nanotechnology-Enabled Medicines

On October 25, 2023 Flashpoint Therapeutics, a company developing nanotechnology-enabled therapeutics for cancer and other diseases, reported a $10M seed financing round led by Beta Lab, a leading deep tech venture capital firm headquartered in Riyadh, Saudi Arabia, with participation from leading private equity investor Russell Carson’s CS Venture Opportunities Fund (Press release, Flashpoint Therapeutics, OCT 25, 2023, View Source [SID1234636352]).

The funding will be used to advance its first therapeutic candidate in oncology, nominate a second development candidate, and advance multiple internal and partnered discovery programs. Flashpoint will also use the funds to expand its team and enhance the platform to develop best-in-class multi-targeted RNA, CRISPR and peptide therapeutics with unique characteristics.

Flashpoint nanostructures are all-in-one formulations that kinetically tune and co-deliver precise combinations of therapeutic components. This approach overcomes limitations of current technologies that rely on mixing therapeutic components with little control over their co-delivery or structural presentation. The company’s proprietary discovery platform is founded on nanotechnology research developed over the past 10 years in the laboratory of Chad Mirkin, Director of the International Institute for Nanotechnology at Northwestern University.

Validated in numerous in-vivo models, this technology enables the development of therapeutic candidates with superior product profiles by co-delivering diverse payloads to the right target cells with precise stoichiometry, optimized structure-function relationship, and synchronized activation kinetics. This capability overcomes many major limitations of current therapeutics that have focused on defining potent components but cannot control how they work together.

"We are thrilled to announce a $10 million seed financing round led by Beta Lab, a leading deep tech venture capital firm," said Adam Margolin, Ph.D., CEO & Founder, Flashpoint Therapeutics. "Biotechnology has created tools capable of modulating any disease process. To translate these tools into cures, we need to get the right combinations into the right cells in the right structure to induce their function at the right time. By solving these challenges for the first time, Flashpoint’s technology has consistently transformed ineffective components into highly effective therapies based on preclinical studies. This substantial investment will allow us to move our candidates into the clinic."

The company’s initial candidate will be a first-in-class cancer immunotherapy that delivers precise cocktails of immune stimulatory molecules with nanoscale architecture and activation kinetics optimized to induce robust, coordinated anti-tumor immune response. This approach yields 35 times increased co-delivery of therapeutic components to immune cells, 80 times stronger immune activation, and 650% greater tumor killing.

Using the same drug components that are ineffective in conventional formulations, Flashpoint immunotherapies have shown promise for treating breast cancer, lymphoma, cervical cancer, melanoma, colon cancer, glioma, and prostate cancer. Based on these studies, the company will advance the best of these candidates into clinical trials.

"Effective cancer therapy requires co-activating multiple pathways in the same cell. But current drugs just mix together components and hope they randomly come together at the right place and time. Flashpoint overcomes limitations of this approach by integrating therapeutic components within nanostructures that control their co-delivery and coordinated activation of the multiple pathways required for the immune system to kill tumors," said Mirkin.

Preclinical studies beyond immuno-oncology have demonstrated that Flashpoint’s technology can enhance virtually all therapeutic modalities – including RNA, peptide, and CRISPR – by enabling superior uptake by target cells outside of the liver, cargo co-delivery, stability in circulation, target activation, and reduced immunogenicity.

A proof of concept clinical study using Flashpoint’s technology has demonstrated delivery of nucleic acid cargo to the brain. Flashpoint plans to partner with leading companies in nucleic acid and peptide therapeutics to develop best-in-class therapeutic candidates in these areas.

"Flashpoint’s technology stands out from other treatment modalities in the market. Extensive data shows its ability to consistently improve therapy effectiveness, and the platform’s elegant design allows it to be added to existing candidates. Any company partnering with Flashpoint stands to gain a unique advantage over the competition. It would be almost negligent not to test if Flashpoint’s platform can enhance candidates in their pipeline," said Abdulrahman Al-Olayen, Managing Director of Beta Lab. Adam brings a deeply personal mission to the company. Motivated by the loss of his mother to cancer at a young age, he has dedicated his career to developing novel cancer therapies. We are eager to support Adam in his passionate mission to develop a new class of breakthrough therapies to benefit patients."

"We invest in transformative technologies and Flashpoint’s superior technologies have the potential to transform the way that therapeutics are developed, said Quinten Stevens, General Partner of CS Venture Opportunities Fund. Professor Chad Mirkin is a visionary, and this marks our second Chad founded company portfolio investment. We are delighted to partner with Chad and Adam and support them in successfully growing Flashpoint and developing their technologies, which will have a material benefit to society.

TriSalus Life Sciences Announces Late Breaker and Additional Data Presentations on Liver Metastases and Pancreatic Cancer at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

On October 25, 2023 TriSalus Life Sciences Inc., (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, reported that it will present a variety of new data from its innovative clinical development pipeline at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 38th Annual Meeting being held November 1-5, 2023, in San Diego, California (Press release, TriSalus Life Sciences, OCT 25, 2023, View Source [SID1234636351]).

Presentation details for SITC (Free SITC Whitepaper) 2023 are as follows:

Late Breaker Oral Presentation: Clinical Activity of SD-101 with Immune Checkpoint Inhibition (ICI) in Metastatic Uveal Melanoma Liver Metastasis (MUM-LM) from the PERIO-01 Phase 1 Trial
Presenter: Sapan P. Patel, M.D., Director of the Uveal Melanoma Program, The University of Texas MD Anderson Cancer Center
Abstract: 1534
Session: Late-Breaking Abstract Session
Time: Saturday, November 4, 11:25 a.m. PDT
Poster Presentation also available in the Poster Hall and in the Virtual ePoster Hall

Poster Presentation: PERIO-03: Pressure Enabled Intrapancreatic Delivery of SD-101 with Checkpoint Blockade for Locally Advanced Pancreatic Adenocarcinoma – Initial Safety and Feasibility Experience
Abstract: 647
Presenter: Michael S. Lee, M.D., Associate Professor, The University of Texas MD Anderson Cancer Center
Time: Friday, November 3, 9:00 a.m. – 7:00 p.m. PDT

Poster Presentation: Checkpoint Inhibitor Administered Either Systemically of Subcutaneously Enhances the Anti-Tumor Immunity of SD-101 Delivered by Pressure-enabled Drug Delivery (PEDD) Device in Treating Liver Metastasis (LM)
Abstract: 1123
Presenter: Chandra C. Ghosh, Ph.D., TriSalus Life Sciences
Time: Friday, November 3, 9:00 a.m. – 7:00 p.m. PDT

The presentations will be available here following their respective sessions.